U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H24N2.C3H6O3
Molecular Weight 370.4852
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAMIPINE LACTATE

SMILES

CC(O)C(O)=O.CN1CCC(CC1)N(CC2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=VUNFQOFEWHEROV-UHFFFAOYSA-N
InChI=1S/C19H24N2.C3H6O3/c1-20-14-12-19(13-15-20)21(18-10-6-3-7-11-18)16-17-8-4-2-5-9-17;1-2(4)3(5)6/h2-11,19H,12-16H2,1H3;2,4H,1H3,(H,5,6)

HIDE SMILES / InChI

Molecular Formula C3H6O3
Molecular Weight 90.0779
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula C19H24N2
Molecular Weight 280.4073
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bamipine (trade name Soventol) is a sedating antihistamine with pronounced sedative effects. Bamipine is a pharmaceutical drug acting as an H1 antihistamine with anticholinergic properties. It is used as an antipruritic ointment. Bamipine hydrochloride has been given by mouth. Bamipine, bamipine lactate, and bamipine salicylate have all been applied topically.

CNS Activity

Curator's Comment: Bamipine is an antihistamine with pronounced sedative effects.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Soventol

Approved Use

Allergic conditions
PubMed

PubMed

TitleDatePubMed
Hybrid approach for the design of highly affine and selective dopamine D(3) receptor ligands using privileged scaffolds of biogenic amine GPCR ligands.
2007 Dec 1
Antimycobacterial and H1-antihistaminic activity of 2-substituted piperidine derivatives.
2008 Dec 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can be used topically: A thin layer applied on the surface of the skin. Re-application is possible in 30 min. Duration of treatment depends on allergic process. http://www.druginfosys.com/drug.aspx?drugcode=1567&type=1
The recommended dose is 50-100 mg 3-4 times/day.
Route of Administration: Oral
Bamipine treatment resulted in 29% of inhibition of Mycobacterium tuberculosis H37Rv (after 4 days by microplate alamar blue assay) at 6.25 ug/mL.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:35:25 UTC 2023
Edited
by admin
on Fri Dec 15 17:35:25 UTC 2023
Record UNII
6K8KNJ07D8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAMIPINE LACTATE
WHO-DD  
Common Name English
MULTIFUNGIN COMPONENT BAMIPINE LACTATE
Brand Name English
Bamipine lactate [WHO-DD]
Common Name English
4-PIPERIDINAMINE, 1-METHYL-N-PHENYL-N-(PHENYLMETHYL)-, MONO(2-HYDROXYPROPANOATE)
Common Name English
PROPANOIC ACID, 2-HYDROXY-, COMPD. WITH 1-METHYL-N-PHENYL-N-(PHENYLMETHYL)-4-PIPERIDINAMINE (1:1)
Common Name English
BAMIPINE LACTATE COMPONENT OF MULTIFUNGIN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29578
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
Code System Code Type Description
SMS_ID
100000084971
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
ECHA (EC/EINECS)
262-887-2
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
MESH
C020867
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
EVMPD
SUB00663MIG
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
RXCUI
236530
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY RxNorm
NCI_THESAURUS
C97686
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
PUBCHEM
11462853
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
FDA UNII
6K8KNJ07D8
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
CAS
61670-09-5
Created by admin on Fri Dec 15 17:35:25 UTC 2023 , Edited by admin on Fri Dec 15 17:35:25 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY